Effects of a 5-HT₄ receptor agonist on oesophageal function and gastro-oesophageal reflux: studies using combined impedance-manometry and combined impedance-pH

Authors: TUTUIAN, R.¹; MAINIE, I.¹; ALLAN, R.²; HARGREAVES, K.²; AGRAWAL, A.¹; FREEMAN, J.¹; GALE, J.²; CASTELL, D. O.¹

Source: Alimentary Pharmacology & Therapeutics, Volume 24, Number 1, July 2006 , pp. 155-162(8)

Publisher: Wiley-Blackwell

Buy & download fulltext article:

You have access to the full text article on a website external to ingentaconnect.

Please click here to view this article on Wiley Online Library.

You may be required to register and activate access on Wiley Online Library before you can obtain the full text. If you have any queries please visit Wiley Online Library

Abstract:

Summary Background

5-HT₄ receptor agonists are used as promotility agents of the stomach, small and large intestine. There is limited information on the influence of 5-HT₄ receptor agonists on oesophageal function and gastro-oesophageal reflux. Aim

To evaluate the effects of tegaserod, a 5-HT₄ agonist on oesophageal function using impedance-manometry and postprandial reflux using impedance-pH monitoring. Methods

Twenty healthy volunteers were enrolled in a double-blind randomized three-period crossover placebo-controlled study. Impedance-manometry and impedance-pH monitoring after a refluxogenic meal were performed at baseline and after 2 days of dosing with tegaserod 6 mg b.d. or placebo. Multichannel intraluminal impedance-EM recorded pressure and bolus transit data during standardized swallows. Multichannel intraluminal impedance-pH monitoring recorded the number of 2-h postprandial acid and non-acid reflux episodes. Results

We found no significant difference in distal oesophageal amplitude when subjects received placebo (median 94.5; range: 53-243 mmHg) or tegaserod (93.6; 43-216 mmHg). Bolus transit time was similar during dosing with placebo (7.1; 5.3-9.4 s) and tegaserod (7.2; 5.9-11.1 s). We observed similar numbers of acid and non-acid reflux episodes during dosing with placebo (5; 0-15 and 3; 0-18, respectively) and tegaserod (2; 0-11 and 4; 0-19, respectively). Conclusion

Tegaserod, a 5-HT₄ receptor agonist does not change oesophageal motility and gastro-oesophageal reflux parameters in healthy volunteers.

Document Type: Research article

DOI: http://dx.doi.org/10.1111/j.1365-2036.2006.02968.x

Affiliations: 1: Division of Gastroenterology and Hepatology, Medical University of South Carolina, Charleston, SC, USA 2: Translational Medicine, Clinical R & D, Pfizer Global R&D, Sandwich, Kent, UK

Publication date: 2006-07-01